
    
      This is a prospective, multicentre phase II study in adult patients with documented MMM and
      requiring therapy for their disease. Patients will be treated every 3 weeks with 4 mg
      zoledronic acid (Zometa), administered by a 15 min. intravenous infusion. Study duration is
      36 weeks (12 infusions). After the study it is recommended to continue treatment until
      disease progression, or the occurrence of unacceptable treatment-related toxicity.

      Objectives of the trial are:

      Primary objectives: the effect of monthly infusion of zoledronic acid 4 mg on:

      hemoglobin level, spleen size

      Secondary objectives the effect of monthly infusion of zoledronic acid 4 mg on: red blood
      cell transfusion need performance status constitutional symptoms leukocyte count thrombocyte
      count bone marrow fibrosis serum LDH
    
  